Shares of Biovail ( BVF) were rising in premarket trading after it and license partner GlaxoSmithKline ( GSK) got word from the FDA that their Wellbutrin XL antidepressant is en route to approval for a more serious condition.

The companies received an FDA approvable letter seeking a few routine clarifications, and the drug companies expect the treatment to be approved in the second half of 2003. Biovail licensed the pill in 2001 to Glaxo, for whom it manufactures and supplies it.

The companies are seeking clearance to market the drug for severe depressive disorder in patients over 18.

Biovail was recently up $2, or 4.3%, to $48. Glaxo was down 18 cents, or 0.4%, to $41.21.

More from Stocks

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Stocks Weaken Around The World as Trump Opens New Fronts in Global Trade War

Stocks Weaken Around The World as Trump Opens New Fronts in Global Trade War

Trump Puts Tech in Trade War Crosshairs With Planned Curb on China Investment

Trump Puts Tech in Trade War Crosshairs With Planned Curb on China Investment

Trump, Trade Wars, General Electric, 'Jurassic World' - 5 Things You Must Know

Trump, Trade Wars, General Electric, 'Jurassic World' - 5 Things You Must Know

Markets Look Confused After Latest Beating

Markets Look Confused After Latest Beating